BIOCRYST PHARMACEUTICALS INC (BCRX) Stock News

NASDAQ:BCRX - Nasdaq - US09058V1035 - Common Stock - Currency: USD

8.3 -0.05 (-0.6%)

After market: 8.3 0 (0%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BCRX Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Chartmill

News Image

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Exceeds Q2 2025 Expectations with Robust Revenue and Profit Growth

3 days ago - By: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 days ago - By: The Motley Fool

BioCryst (BCRX) Q2 Revenue Jumps 50%

5 days ago - By: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

5 days ago - By: Benzinga - Mentions: VRTX RHP NVTS MSA ...

Earnings Scheduled For August 4, 2025

8 days ago - By: Benzinga

Earnings Outlook For BioCryst Pharma

9 days ago - By: BioCryst Pharmaceuticals, Inc.

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

11 days ago - By: Zacks Investment Research - Mentions: ESPR

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

19 days ago - By: BioCryst Pharmaceuticals, Inc.

BioCryst to Report Second Quarter 2025 Financial Results on August 4

a month ago - By: Yahoo Finance - Mentions: RY RY.CA WVE

RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13

a month ago - By: Zacks Investment Research - Mentions: CAH

Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?

a month ago - By: BioCryst Pharmaceuticals, Inc.

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

a month ago - By: Yahoo Finance - Mentions: DVAX

Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31

a month ago - By: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: BioCryst Pharmaceuticals, Inc.

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

2 months ago - By: BioCryst Pharmaceuticals, Inc.

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

2 months ago - By: BioCryst Pharmaceuticals, Inc.

ORLADEYO® (berotralstat) Approved in Colombia

2 months ago - By: BioCryst Pharmaceuticals, Inc.

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

2 months ago - By: Zacks Investment Research

BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy?

2 months ago - By: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: BioCryst Pharmaceuticals, Inc.

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

2 months ago - By: BioCryst Pharmaceuticals, Inc.

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

2 months ago - By: Zacks Investment Research

Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?

2 months ago - By: BioCryst Pharmaceuticals, Inc.

BioCryst to Present at Upcoming Investor Conferences

3 months ago - By: Zacks Investment Research

Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade

3 months ago - By: BioCryst Pharmaceuticals, Inc.

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

3 months ago - By: Zacks Investment Research - Mentions: RMBS WYY

Best Momentum Stocks to Buy for May 9th

3 months ago - By: Zacks Investment Research - Mentions: FMS WYY CBNA

New Strong Buy Stocks for May 9th

3 months ago - By: Zacks Investment Research

Why BioCryst (BCRX) Might be Well Poised for a Surge

3 months ago - By: Zacks Investment Research

Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect?